Martin Shkreli is an investor and entrepreneur who co-founded DL Software, the company that operates the Godel Terminal financial information system, and in December 2025 was named a strategic advisor to the optical-computing developer Q/C Technologies. He co-founded the hedge fund MSMB Capital Management in 2009, founded the biotech company Retrophin in 2011 and was its chief executive until 2014, and founded Turing Pharmaceuticals in 2015. In August 2017 a federal jury convicted him of two counts of securities fraud and one count of conspiracy to commit securities fraud in a case concerning the MSMB funds and Retrophin; he was sentenced in March 2018 to seven years in prison and was released to a halfway house in May 2022. In January 2022 a federal judge, ruling in an antitrust case brought by the Federal Trade Commission and seven states over the drug Daraprim, barred him for life from the pharmaceutical industry and ordered him to pay $64.6 million in disgorgement; the Second Circuit affirmed the ruling in January 2024. His market commentary focuses on biotech and technology stocks.
Martin Shkreli has 38 trade ideas tracked on Buzzberg across 36 tickers since November 2025. Win rate 65% across 37 evaluated calls, average return +6.1%. Ranked #374 on Buzzberg's 30-day Authors leaderboard. Most covered: NVDA, QCLS, RXRX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
#44Ranked Speaker
#44 on Buzzberg Alpha
Horizon: 7D